SONN•benzinga•
Sonnet BioTherapeutics shares are trading higher after the company announced the issuance of a U.S. patent covering an IL-18 variant into two novel immunotherapeutic drug candidates.
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 6, 2024 by benzinga